Advanced pre-clinical evaluations

The collaboration with the BITTA laboratory allows the validation on animal models of the use of cell and/or drug therapy for tissue regeneration or treatment of specific diseases (e.g. rheumatic diseases, osteoarthritis, muscular dystrophy). Moreover, the use of transgenic animals enables to characterize the role of specific genes and proteins involved in the pathological processes.

In the laboratory cultures of chondrocytes, synoviocytes, osteoblasts, osteocytes, tenocytes, ligament cells and mesenchymal cells isolated from patients with osteoarthritis (OA) and rheumatoid arthritis (RA) are available in order to identify possible therapeutic targets (especially with regard to the signalling mechanisms that control cartilage tissue inflammation and degeneration). Such cultures are also used to evaluate the activity of molecules or drugs to treat OA and/or RA or other diseases (viability, proliferation, cytotoxicity, apoptosis and anti-inflammatory action).
The collaboration with the BITTA laboratory allows to perform on animal models advanced preclinical studies such as cell therapies for the treatment of specific diseases (e.g. rheumatic diseases, osteoarthritis, muscular dystrophy). Moreover, the use of transgenic animals enables to characterize the role of specific genes and proteins involved in the pathological process.

Figure 10. Schematic representation of the anabolic and catabolic processes regulating cartilage matrix homeostasis

Figure 11. Rabbit femoral condyles histological analysis performed by Safranin O and Fast Green staining

Figure 12. In vivo biodistribution of labeled mesenchymal stem cells

Content updated 13/02/2015 - 15:59
Utilizza SharethisShareThis  Scrivi una email  Vai a facebook  Vai a twitter